Ajai Chari, MD, from the Mount Sinai School of Medicine, discusses next steps for the TRiMM-2 study, which is investigating teclistamab and talquetamab in combination with daratumumab in relapsed/refractory multiple myeloma patients. Results from this study were recently presented in two abstracts at ASH 2021.
Multiple myeloma is a rare blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Myeloma cells also produce inactive clones of abnormal antibodies that may negatively affect the bones and kidneys. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation. While the disease is treatable, relapses are common and some patients are refractory to first line treatment.
The TRiMM-2 study (NCT04108195) is an ongoing phase 1b study, the purpose of which is to identify recommended phase 2 doses for each treatment combination. As explained previously, data from the study was presented in two ASH 2021 that support further clinical development of talquetamab plus daratumumab combination therapy.
As Dr. Chari explains, next steps for the TRiMM study is long-term data as PFS has not been determined, even in studies of talquetamab and teclistamab as monotherapies. Additionally, data from the cohort receiving pomalidomide in addition to teclistamab plus daratumumab will also be invaluable.
To learn more about multiple myeloma and other rare cancers, visit checkrare.com/diseases/cancers/